NcXHF

EPITHELIAL OVARIAN CANCER IN OLDER WOMEN
relationship of patient age and paclitaxel clinical pharmacology: Cancer
and Leukemia Group B (CALGB 9762). J Clin Oncol. 2006;24:1846-
1851.
50. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinumbased
chemotherapy versus conventional platinum-based chemotherapy
in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-
2.2 trial. Lancet. 2003;361:2099-2106.
51. Pfısterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared
with carboplatin in patients with platinum-sensitive recurrent
ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG,
and the EORTC GCG. J Clin Oncol. 2006;24:4699-4707.
52. Kurtz JE, Kaminsky MC, Floquet A, et al. Ovarian cancer in elderly patients:
carboplatin and pegylated liposomal doxorubicin versus carboplatin
and paclitaxel in late relapse—a Gynecologic Cancer Intergroup
(GCIG) CALYPSO sub-study. Ann Oncol. 2011;22:2417-2423.
53. Bukowski RM, Ozols RF, Markman M. The management of recurrent
ovarian cancer. Semin Oncol. 2007;34 (2 suppl 2):S1-S15.
54. Gridelli C, Langer C, Maione P, et al. Lung cancer in the elderly. J Clin
Oncol. 2007;25:1898-1907.
55. Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in
elderly individuals: recommendations of the International Society of
Geriatric Oncology. Lancet Oncol. 2007;8:1101-1115.
56. Gronlund B, Høgdall C, Hansen HH, et al. Performance status rather
than age is the key prognostic factor in second-line treatment of elderly
patients with epithelial ovarian carcinoma. Cancer. 2002;94:1961-1967.
57. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for
women treated with pegylated liposomal doxorubicin compared with
topotecan in a phase 3 randomized study of recurrent and refractory
epithelial ovarian cancer. Gynecol Oncol. 2004;95:1-8.
58. Morris RT. Weekly topotecan in the management of ovarian cancer.
Gynecol Oncol. 2003;90 (3 pt 2):S34-S38.
59. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined
with chemotherapy for platinum-resistant recurrent ovarian cancer: the
AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:
1302-1308.
60. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in
persistent or recurrent epithelial ovarian cancer or primary peritoneal
cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:
5165-5171.
61. Lewin SN, Buttin BM, Powell MA, et al. Resource utilization for ovarian
cancer patients at the end of life: how much is too much? Gynecol Oncol.
2005;99:261-266.
62. Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment
in cooperative group clinical cancer trials: CALGB 360401.
J Clin Oncol. 2011;29:1290-1296.
63. Kanesvaran R, Li H, Koo KN, et al. Analysis of prognostic factors of
comprehensive geriatric assessment and development of a clinical scoring
system in elderly Asian patients with cancer. J Clin Oncol. 2011;29:
3620-3627.
64. PACE participants, Audisio RA, Pope D, et al. Shall we operate? Preoperative
assessment in elderly cancer patients (PACE) can help. A SIOG
surgical task force prospective study. Crit Rev Oncol Hematol. 2008;65:
156-163.
65. Pope D, Ramesh H, Gennari R, et al. Pre-operative assessment of cancer
in the elderly (PACE): a comprehensive assessment of underlying characteristics
of elderly cancer patients prior to elective surgery. Surg Oncol.
2006;15:189-197.
66. Chow WB, Rosenthal RA, Merkow RP, et al. Optimal preoperative assessment
of the geriatric surgical patient: a best practices guideline from
the American College of Surgeons National Surgical Quality Improvement
Program and the American Geriatrics Society. J Am Coll Surg.
2012;215:453-466.
67. Huisman MG, van Leeuwen BL, Ugolini G, et al. Timed up & go: a
screening tool for predicting 30-day morbidity in onco-geriatric surgical
patients? A multicenter cohort study. PloS One. 2014;9:e86863.
68. Won E, Hurria A, Feng T, et al. CA125 level association with chemotherapy
toxicity and functional status in older women with ovarian cancer.
Int J Gynecol Cancer. 2013;23:1022-1028.
69. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or
primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;
363:943-953.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e321